Development and Characterization of a Guinea Pig-Adapted Sudan Virus

Author:

Wong Gary12,He Shihua1,Wei Haiyan13,Kroeker Andrea12,Audet Jonathan12,Leung Anders1,Cutts Todd4,Graham Jill5,Kobasa Darwyn12,Embury-Hyatt Carissa5,Kobinger Gary P.1267,Qiu Xiangguo12

Affiliation:

1. Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada

2. Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada

3. Institute of Infectious Disease, Henan Centre for Disease Control, Henan, China

4. Applied Biosafety and Research Program, JC Wilt Infectious Diseases Research Centre, Public Health Agency of Canada, Winnipeg, Manitoba, Canada

5. Canadian Food Inspection Agency, National Centre for Foreign Animal Disease, Winnipeg, Manitoba, Canada

6. Department of Immunology, University of Manitoba, Winnipeg, Manitoba, Canada

7. Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA

Abstract

ABSTRACT Infections with Sudan virus (SUDV), a member of the genus Ebolavirus , result in a severe hemorrhagic fever with a fatal outcome in over 50% of human cases. The paucity of prophylactics and therapeutics against SUDV is attributed to the lack of a small-animal model to screen promising compounds. By repeatedly passaging SUDV within the livers and spleens of guinea pigs in vivo , a guinea pig-adapted SUDV variant (SUDV-GA) uniformly lethal to these animals, with a 50% lethal dose (LD 50 ) of 5.3 × 10 −2 50% tissue culture infective doses (TCID 50 ), was developed. Animals infected with SUDV-GA developed high viremia and died between 9 and 14 days postinfection. Several hallmarks of SUDV infection, including lymphadenopathy, increased liver enzyme activities, and coagulation abnormalities, were observed. Virological analyses and gross pathology, histopathology, and immunohistochemistry findings indicate that SUDV-GA replicates in the livers and spleens of infected animals similarly to SUDV infections in nonhuman primates. These developments will accelerate the development of specific medical countermeasures in preparation for a future disease outbreak due to SUDV. IMPORTANCE A disease outbreak due to Ebola virus (EBOV), suspected to have emerged during December 2013 in Guinea, with over 11,000 dead and 28,000 infected, is finally winding down. Experimental EBOV vaccines and treatments were administered to patients under compassionate circumstances with promising results, and availability of an approved countermeasure appears to be close. However, the same range of experimental candidates against a potential disease outbreak caused by other members of the genus Ebolavirus , such as Sudan virus (SUDV), is not readily available. One bottleneck contributing to this situation is the lack of a small-animal model to screen promising drugs in an efficient and economical manner. To address this, we have generated a SUDV variant (SUDV-GA) that is uniformly lethal to guinea pigs. Animals infected with SUDV-GA develop disease similar to that of SUDV-infected humans and monkeys. We believe that this model will significantly accelerate the development of life-saving measures against SUDV infections.

Funder

Canadian Safety and Security Program

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

Reference24 articles.

1. Ebola haemorrhagic fever in Zaire, 1976. Report of an international commission;WHO;Bull World Health Organ,1978

2. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/international study team;WHO;Bull World Health Organ,1978

3. WHO International. 2015 posting date. Ebola situation report 30 September 2015. World Health Organization Geneva Switzerland. http://apps.who.int/ebola/current-situation/ebola-situation-report-30-september-2015.

4. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses

5. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge;Stanley DA;Nat Med,2014

Cited by 42 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control;Signal Transduction and Targeted Therapy;2024-09-11

2. Animal Models for Infectious Disease Vaccine Development;A Comprehensive Guide to Toxicology in Nonclinical Drug Development;2024

3. Filoviruses: Scientific Gaps and Prototype Pathogen Recommendation;The Journal of Infectious Diseases;2023-10-15

4. A single dose intranasal combination panebolavirus vaccine;The Journal of Infectious Diseases;2023-07-20

5. The rVSV-EBOV vaccine provides limited cross-protection against Sudan virus in guinea pigs;npj Vaccines;2023-06-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3